{"schema_version":"1.0","type":"article","title":"Revolution Medicines: Why Biotech Winners Need Capital Strategy, Not Just Good Science","url":"https://drugnews.com.tw/articles/2026-06-14-revolution-medicines-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-14-revolution-medicines-en.md","lang":"en","date":"2026-06-14","publish_at":"2026-06-14T00:54:00.739Z","updated_at":"2026-06-14","category":"商業分析系列","topic":"商業分析系列","tags":["RAS","Revolution Medicines","Daraxonrasib","Biotech financing","Pancreatic cancer","Capital markets"],"summary":"Revolution Medicines shows why next-generation biotech companies need to convert clinical momentum into capital momentum if they want to finish expensive global drug-development races.","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"RAS value creation","url":"https://drugnews.com.tw/assets/articles/revolution-medicines-en/figure-01.png"},{"alt":"Financing rhythm","url":"https://drugnews.com.tw/assets/articles/revolution-medicines-en/figure-02.png"},{"alt":"Science x capital","url":"https://drugnews.com.tw/assets/articles/revolution-medicines-en/figure-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/revolution-medicines-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-14）。Revolution Medicines: Why Biotech Winners Need Capital Strategy, Not Just Good Science。https://drugnews.com.tw/articles/2026-06-14-revolution-medicines-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-14-revolution-medicines.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}